Monitoring and Screening HINF 371 - Medical Methodologies Session 10.

Slides:



Advertisements
Similar presentations
Screening and Prevention
Advertisements

SCID Review Discussion. Decision Matrix Key Questions 1.This is the overarching question for the evidence review: Is there direct evidence that screening.
Prevention and Screening MMS Year 4 Public Health Workshop in O&G.
©PPRNet 2014 Designing a PPRNet PCORI Application to Improve Adherence to USPSTF Grade D Recommendations for Cancer Screening.
Introduction Medication non adherence ( noncompliance) remains a major problem. You have to assess and treat adherence related problems that can adversely.
Risk Adjustment Hierarchical Condition Categories (HCC Coding)
1 Case-Control Study Design Two groups are selected, one of people with the disease (cases), and the other of people with the same general characteristics.
Public Health Perspective on Radon Control in Ireland Dr. Ina Kelly Specialist Registrar in Public Health Medicine Health Service Executive Department.
CVD prevention & management: a new approach for primary care Rod Jackson School of Population Health University of Auckland New Zealand.
Disability, Frailty and Co-morbidity Gero 302 Jan 2012.
Overview of Medical Decision Making HINF Medical Methodologies Session 2.
Diagnosing – Critical Activity HINF Medical Methodologies Session 7.
Health Promotion and Improvements Methods
Vanderbilt Sports Medicine Chapter 4: Prognosis Presented by: Laurie Huston and Kurt Spindler Evidence-Based Medicine How to Practice and Teach EBM.
Statistics for Health Care
Prof. Wasantha Gunathunga.  Primary  Secondary  Tertiary.
 men Differences in Blood Pressure Documentation and Clinical Practice Variability: Implications for Population Management for Hypertension and Opportunities.
Asking Questions Robert M. Rowell, DC, MS.
HealthSmarts Keeping Tabs On Your Health. Prevention Primary Secondary Tertiary.
Source: Site Name and Year IHS Diabetes Audit Diabetes Health Status Report ______Site Name_________ Health Outcomes and Care Given to Patients with Diabetes.
The Nature of Disease.
Rapid E clinical guidance in the management of Type 2 diabetes New Zealand Guidelines Group.
Hong Kong Poland and non- communicable diseases More and more people in our country suffer from circulatory system diseases, tumors, osteoporosis,
Screening Dr Gerry Bryant. What is screening? Systematic application of a test or enquiry, to identify individuals at sufficient risk of a specific disorder.
BIOE 301 Lecture Seventeen. Guest Speaker Jay Brollier World Camp Malawi.
Screening Introduction to Primary Care:
PEBB Board Presentation Kaiser 2006 Quality Initiatives.
Healthcare Reform The “Affordable Care Act” How Will It Affect Substance Abuse Care?
PERIODIC MEDICAL EXAMINATION BY DR. ANGELA ESOIMEME MBBS, MPH, FWACGP.
Section 5: Configuration of healthcare to manage CKD.
PTSC Week October 2010© Marilyn Hughes Gaston, M.D. and Gayle K. Porter, Psy.D., Rev All Rights Reserved. Prime Time Sister Circles.
Dr K N Prasad Community Medicine
1 SCREENING. 2 Why screen? Who wants to screen? n Doctors n Labs n Hospitals n Drug companies n Public n Who doesn’t ?
Cancer Prevention Eyad Alsaeed, MD,FRCPC Consultant Radiation Oncology PSHOC KFMC.
BIOE 301 Lecture Seventeen. Progression of Heart Disease High Blood Pressure High Cholesterol Levels Atherosclerosis Ischemia Heart Attack Heart Failure.
Screening Puja Myles
Cost-effectiveness of Screening Tests Mark Hlatky, MD Stanford University.
Principles of Screening
Screening and its Useful Tools Thomas Songer, PhD Basic Epidemiology South Asian Cardiovascular Research Methodology Workshop.
Women’s Health Evening Portishead Medical Group Monday 12 th October pm.
Mark Clanton, M.D. M.P.H. Deputy Director Cancer Care Delivery Systems Moving Discovery Through to Delivery: A Critical Opportunity for Leadership and.
Using QOF and Service Specifications to meet HI Needs Rachel Foskett-Tharby.
Unit 15: Screening. Unit 15 Learning Objectives: 1.Understand the role of screening in the secondary prevention of disease. 2.Recognize the characteristics.
Clinical Epidemiology and Evidence-based Medicine Unit FKUI – RSCM
Pharmacy in Public Health: Levels of Disease Prevention Add course Date here.
© 2010 Jones and Bartlett Publishers, LLC. Chapter 12 Clinical Epidemiology.
What are the Chances Dr? Nick Pendleton. Can I have a Prostate Check? ?
Chapter 7: Epidemiology of Chronic Diseases. “The Change You Like to See….” (1 of 3) Chronic diseases result from prolongation of acute illness. – With.
Copyright © 2008 Delmar. All rights reserved. Chapter 4 Epidemiology and Public Health Nursing.
Screening Tests: A Review. Learning Objectives: 1.Understand the role of screening in the secondary prevention of disease. 2.Recognize the characteristics.
كلية العلوم الصحية بالليث
IE 485 «Decision Making in Health Care»
Cancer prevention and early detection
Clinical Epidemiology

Cancer prevention and early detection
Well Child Care.
Hypertension November 2016
Definition of Cancer Screening
How do we delay disease progress once it has started?
Natural History of Disease
Health and Disease Management
Section 5: Configuration of healthcare to manage CKD
Hypertension November 2016
Introduction to Epidemiology
Screening and Prevention
Basic statistics.
Meeting with EG PHC Ev. underrubrik Förnamn Efternamn.
Presentation transcript:

Monitoring and Screening HINF Medical Methodologies Session 10

Objective Understand the function of screening and monitoring in the continuum of disease progression Understand the function of screening and monitoring in the continuum of disease progression Understand the factors in deciding for screening and monitoring Understand the factors in deciding for screening and monitoring

Reading Mar CD, Doust J, Glasziou (2006) Chapter 7: Monitoring in Chronic Disease, Blackwell Publishing and BMJ Books, USA Mar CD, Doust J, Glasziou (2006) Chapter 7: Monitoring in Chronic Disease, Blackwell Publishing and BMJ Books, USA Mar CD, Doust J, Glasziou (2006) Chapter 8: Screening for disease, health promotion and disease prevention, Blackwell Publishing and BMJ Books, USA Mar CD, Doust J, Glasziou (2006) Chapter 8: Screening for disease, health promotion and disease prevention, Blackwell Publishing and BMJ Books, USA

Quick discussion about assignment types possible 1. Current structure – questions and answers (4 of them) 2. Introduction of a case and development of the decision (one of two assignments for the term) 3. Data given for a health region and decisions for program development (single assignment for the term) 4. Student presentations of topics (considered one assignment)

Prevention and Screening Aim is to reduce the risk of death and morbidity by reducing the exposure to risk factors for disease before the process even starts (health promotion) or by providing interventions that prevent the disease from ever manifesting (disease prevention) – primary prevention Aim is to reduce the risk of death and morbidity by reducing the exposure to risk factors for disease before the process even starts (health promotion) or by providing interventions that prevent the disease from ever manifesting (disease prevention) – primary prevention

Levels of Prevention Activity What it does Examples Health promotion Interventions that generally improve health for everyone Exercise, stop smoking, eating well Disease prevention Pre-emptively acting before a specific disease manifests Vaccination, Seat belts, cycle helmets Disease screening Look signs of disease before they manifest Mammography, BP measurement, cervical screening Anticipatory care Looking for, and anticipating complications of a disease Db (retinopathy, micovascular damage, neuropathy), CHF (acute crisis, adherence to drugs, diet,exercise)

Screening Preferred - Pre-test probability is high and test is highly sensitive Preferred - Pre-test probability is high and test is highly sensitive Decision criteria for development Decision criteria for development Is the disease important? Is the disease important? Is there an effective test? Is there an effective test? Is there an effective treatment? Is there an effective treatment? Is the test affordable and acceptable? Is the test affordable and acceptable? Decision criteria for use Decision criteria for use Is the effective treatment more effective in early stages? Is the effective treatment more effective in early stages? Do benefits outweigh harms? Do benefits outweigh harms? Is the test routinely available? Is the test routinely available? Examples: Cervical cancer, prostate cancer, stroke, PKU, Lung Cancer Examples: Cervical cancer, prostate cancer, stroke, PKU, Lung Cancer

Selection of Population to Target High risk groups or all groups High risk groups or all groups High risk groups High risk groups Exposure to the risk factor is more limited within the population Exposure to the risk factor is more limited within the population Where susceptibility following exposure to the risk factor is limited, or where there is a threshold effect Where susceptibility following exposure to the risk factor is limited, or where there is a threshold effect Where it is easier or cheaper to identify persons at high risk Where it is easier or cheaper to identify persons at high risk Intervention is difficult to comply with or carries a significant risk of side effects Intervention is difficult to comply with or carries a significant risk of side effects All groups All groups The target disorder is common and a large proportion of the population is exposed to risk factors for target disorder The target disorder is common and a large proportion of the population is exposed to risk factors for target disorder Where the risk of disease rises continuously with exposure to the risk factor (as occurs with blood pressure and cholesterol levels) Where the risk of disease rises continuously with exposure to the risk factor (as occurs with blood pressure and cholesterol levels) Where it is easier or cheaper to apply an intervention to an entire population than to find and direct the interventions to individuals at high risk of the target disorder Where it is easier or cheaper to apply an intervention to an entire population than to find and direct the interventions to individuals at high risk of the target disorder

Monitoring Periodic measurement followed by adjustment of the management Periodic measurement followed by adjustment of the management External homeastasis External homeastasis Clinical effectiveness versus opportunity cost Clinical effectiveness versus opportunity cost

When to monitor What are the short-term consequences? What are the short-term consequences? What are the long term consequences? What are the long term consequences? Do symptoms give early warning? Do symptoms give early warning?

Phases of Monitoring Pre-treatment (to diagnose) Pre-treatment (to diagnose) Initial titration Initial titration Pharmacokinetics Pharmacokinetics Pharmacodynamics Pharmacodynamics Maintenance Maintenance One recording above 3 SD One recording above 3 SD Two recordings above 2 SD Two recordings above 2 SD Re-establish control Re-establish control Cessation Cessation

Which Measurement Is it a good measure of clinically relevant outcomes? Is it a good measure of clinically relevant outcomes? Proximal targets versus distal targets Proximal targets versus distal targets Can it detect changes in risk rapidly enough? Can it detect changes in risk rapidly enough? “Most relevant outcome that can be assessed reasonably soon” “Most relevant outcome that can be assessed reasonably soon” Is the random variability acceptable, or can it be made acceptable by repeated measurements? Is the random variability acceptable, or can it be made acceptable by repeated measurements? Is it sufficiently affordable, accessible, and acceptable to patients? Is it sufficiently affordable, accessible, and acceptable to patients?

Can it detect changes in risk rapidly enough? Patient adherence  drug concentration  markers of bone turnover  bone mineral density  asymptomatic factures  symptomatic fractures

Patient Monitoring For reporting to physician For reporting to physician For improving the adherence For improving the adherence For early warning For early warning For treatment adjustments? For treatment adjustments?

Common Errors in Monitoring Re-checking too soon Re-checking too soon Over-reacting to changes Over-reacting to changes Over-adjusting therapy Over-adjusting therapy